Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro

Dasatinib treatment for Philadelphia chromosome-positive leukemias

(2009) Hanna Jean Khoury et al.   CANCER

Decreased Bone Turnover Despite Persistent Secondary Hyperparathyroidism during Prolonged Treatment with Imatinib

(2009) Susannah O'Sullivan et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

(2009) F J Giles et al.   LEUKEMIA

Dasatinib in relapsed or plateau-phase multiple myeloma

(2009) Tanya M. Wildes et al.   LEUKEMIA & LYMPHOMA

Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia

(2008) S. Jonsson et al.   HAEMATOLOGICA

PDGF Receptor β Is a Potent Regulator of Mesenchymal Stromal Cell Function

(2008) Ayano Tokunaga et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty

(2008) Stefania Mariani et al.   LANCET

Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor

(2008) N Brownlow et al.   LEUKEMIA

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis

(2008) K Vandyke et al.   LEUKEMIA